A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy
Zhang J, Qu Z, Xiao X, Adelson D, Wang F, Wei A, Harata-Lee Y, Cui J, He D, Xie L, Sun L, Li J, Huang Z, Aung T, Yao H, Lin L. A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy. Heliyon 2024, 11: e41104. PMID: 39844968, PMCID: PMC11750466, DOI: 10.1016/j.heliyon.2024.e41104.Peer-Reviewed Original ResearchEpidermal growth factor receptor tyrosine kinase inhibitorsEGFR-TKI-resistant cell linesNon-small cell lung cancerInhibition of drug resistanceLung cancerEpidermal growth factor receptor tyrosine kinase inhibitor resistanceDrug resistanceGrowth factor receptor tyrosine kinase inhibitorsCell linesReceptor tyrosine kinase inhibitorsEGFR-TKI resistanceResistance to gefitinibCell lung cancerFirst-line treatmentPI3K/AKT/mTOR pathwayMortality of lung cancerEGFR mutationsTreatment failureMolecular mechanismsDose-dependentlyKinase inhibitorsFlow cytometryAnticancer effectsGefitinibH1650 cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply